Risk stratification in therapy-related myelodysplastic syndromes

por Zeidan, Amer M.
Publicado en Oncotarget (2017)

There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes

por Zeidan, Amer M., Komrokji, Rami S.
Publicado 2013

MYELOID DISORDERS AFTER AUTOIMMUNE DISEASE

por Boddu, Prajwal, Zeidan, Amer M.
Publicado en Best Pract Res Clin Haematol (2019)

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

por Zeidan, Amer M, Gore, Steven D
Publicado 2013

New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach

por Zeidan, Amer M., Gore, Steven D.
Publicado en Clin Cancer Res (2014)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes

por Shallis, Rory M., Zeidan, Amer M.
Publicado en BMC Hematol (2018)

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

por Bewersdorf, Jan Philipp, Zeidan, Amer M.
Publicado en Cells (2020)

Following in the footsteps of acute myeloid leukemia: Are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

por Bewersdorf, Jan Philipp, Zeidan, Amer M.
Publicado en Leuk Lymphoma (2020)

Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era

por Bewersdorf, Jan Philipp, Zeidan, Amer M.
Publicado en Expert Rev Hematol (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

por Bewersdorf, Jan Philipp, Zeidan, Amer M.
Publicado en Cancers (Basel) (2021)

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

por Bewersdorf, Jan Philipp, Zeidan, Amer M.
Publicado en Oncotarget (2021)

Current therapy of myelodysplastic syndromes()

por Zeidan, Amer M., Linhares, Yuliya, Gore, Steven D.
Publicado 2013

Iron chelation therapy in myelodysplastic syndromes: where do we stand?

por Mitchell, Mhairi, Gore, Steven D, Zeidan, Amer M
Publicado 2013

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities

por Stahl, Maximilian, Kim, Tae Kon, Zeidan, Amer M
Publicado en World J Stem Cells (2016)

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

por Philipp Bewersdorf, Jan, Stahl, Maximilian, Zeidan, Amer M
Publicado en Expert Rev Anticancer Ther (2019)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

por Lewis, Russell, Bewersdorf, Jan Philipp, Zeidan, Amer M
Publicado en Cancer Manag Res (2021)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

por Allen, Cecily, Zeidan, Amer M., Bewersdorf, Jan Philipp
Publicado en Life (Basel) (2021)

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

por Zeidan, Amer M., Kharfan-Dabaja, Mohamed A., Komrokji, Rami S.
Publicado 2014

EPIGENETIC THERAPY IN ACUTE MYELOID LEUKEMIA: CURRENT AND FUTURE DIRECTIONS

por Kim, Tae Kon, Gore, Steven D., Zeidan, Amer M.
Publicado en Semin Hematol (2015)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia

por Uy, Natalie, Nadeau, Michelle, Stahl, Maximilian, Zeidan, Amer M
Publicado en J Blood Med (2018)